HIV-1 subtype C mosaic Gag expressed by BCG and MVA elicits persistent effector T cell responses in a prime-boost regimen in mice

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Jongwe, Tsungai Ivai ^a   Chapman, Ros ^a   Douglass, Nicola ^a   Chetty, Shivan ^a   Chege, Gerald ^a   Williamson, Anna Lise ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL; BAGG ALBINO MOUSE; FEMALE; GENETICS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOUSE; MYCOBACTERIUM BOVIS; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIROLOGY;

AIDS VACCINES; ANIMALS; BCG VACCINE; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 85014944453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159141     Document Type: Article

References (75)

1. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J, WHO-UNAIDS Network for HIV Isolation and Characterization. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002 Feb 1; 29(2):184–190. PMID: 11832690
2. UNAIDS. Global fact sheet July 2014. Available: http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/factsheet/2014/20140716_FactSheet_en.pdf. Accessed November 2014.
3. Department of Health. Republic of South Africa. Available: www.health-e.org.za/. Accessed November 2014.
4. Van Harmelen JH, Van der Ryst E, Loubser AS, York D, Madurai S, Lyons S, et al. A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS Res Hum Retroviruses 1999 Mar 1; 15(4):395–398. PMID: 10082124
5. Guevara H, Johnston E, Zijenah L, Tobaiwa O, Mason P, Contag C, et al. Prenatal transmission of subtype C HIV-1 in Zimbabwe: HIV-1 RNA and DNA in maternal and cord blood. J Acquir Immune Defic Syndr 2000 Dec 15; 25(5):390–397. PMID: 11141238
6. Bredell H, Martin DP, Van Harmelen J, Varsani A, Sheppard HW, Donovan R, et al. HIV type 1 subtype C gag and nef diversity in Southern Africa. AIDS Res Hum Retroviruses 2007 Mar; 23(3):477–481. PMID: 17411382
7. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999 Jan; 73(1):152–160. PMID: 9847317
8. Tatt ID, Barlow KL, Clewley JP, Gill ON, Parry JV. Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997–2000. J Acquir Immune Defic Syndr 2004 Aug 15; 36(5):1092–1099. PMID: 15247563
9. Gräf T, Pinto AR. The increasing prevalence of HIV-1 subtype C in Southern Brazil and its dispersion through the continent. Virology 2013 1/5; 435(1):170–178. doi: 10.1016/j.virol.2012.08.048 PMID: 22999094
10. Alcalde R, Guimaraes ML, Duarte AJ, Casseb J. Clinical, epidemiological and molecular features of the HIV-1 subtype C and recombinant forms that are circulating in the city of Sao Paulo, Brazil. Virol J 2012 Aug 9; 9:156-422X-9-156.
11. Excler JL, Robb ML, Kim JH. Prospects for a globally effective HIV-1 vaccine. Vaccine 2015 Jun 20.
12. Haynes BF. New approaches to HIV vaccine development. Curr Opin Immunol 2015 Jun 4; 35:39–47. doi: 10.1016/j.coi.2015.05.007 PMID: 26056742
13. Esparza J. A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine. Front Immunol 2015 Mar 18; 6:124. doi: 10.3389/fimmu.2015.00124 PMID: 25852692
14. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007 Jan; 13 (1):46–53. PMID: 17173051
15. Prendergast A, Goodliffe H, Clapson M, Cross R, Tudor-Williams G, Riddell A, et al. Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection. AIDS 2011 Jun 19; 25(10):1329–1331. doi: 10.1097/QAD.0b013e3283478575 PMID: 21505296
16. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol 2012 Jan; 86(1):277–283. doi: 10.1128/JVI.05577-11 PMID: 22031937
17. Tongo M, Burgers WA. Challenges in the design of a T cell vaccine in the context of HIV-1 diversity. Viruses 2014 Oct 23; 6(10):3968–3990. doi: 10.3390/v6103968 PMID: 25341662
18. Mann JK, Ndung'u T. HIV-1 vaccine immunogen design strategies. Virol J 2015 Jan 24; 12:3-014-0221-0.
19. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007 Jan; 13(1):100–106. PMID: 17187074
20. Korber BT, Letvin NL, Haynes BF. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009 Sep; 83(17):8300–8314. doi: 10.1128/JVI.00114-09 PMID: 19439471
21. Santra S, Muldoon M, Watson S, Buzby A, Balachandran H, Carlson KR, et al. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 2012 Jul 5; 428(2):121–127. doi: 10.1016/j.virol.2012.03.012 PMID: 22521913
22. Fenimore PW, Muhammad MA, Fischer WM, Foley BT, Bakken RR, Thurmond JR, et al. Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage. PLoS One 2012; 7(10):e44769. doi: 10.1371/journal.pone.0044769 PMID: 23056184
23. Shedlock DJ, Aviles J, Talbott KT, Wong G, Wu SJ, Villarreal DO, et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 2013 Jul; 21(7):1432–1444. doi: 10.1038/mt.2013.61 PMID: 23670573
24. Goulder PJ, Sewell AK, Lalloo DG, Price DA, Whelan JA, Evans J, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997 Apr 21; 185(8):1423–1433. PMID: 9126923
25. Nkolola JP, Bricault CA, Cheung A, Shields J, Perry J, Kovacs JM, et al. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol 2014 Sep 1; 88(17):9538–9552. doi: 10.1128/ JVI.01739-14 PMID: 24965452
26. Hulot SL, Korber B, Giorgi EE, Vandergrift N, Saunders KO, Balachandran H, et al. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. J Virol 2015 Jun 15; 89(12):6462–6480. doi: 10.1128/JVI.00383-15 PMID: 25855741
27. Hatherill M. Prospects for elimination of childhood tuberculosis: the role of new vaccines. Arch Dis Child 2011 Sep; 96(9):851–856. doi: 10.1136/adc.2011.214494 PMID: 21450742
28. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 2011 Oct 12; 366(1579):2782–2789. doi: 10.1098/rstb.2011.0097 PMID: 21893541
29. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012; 8(5):e1002607. doi: 10.1371/journal.ppat.1002607 PMID: 22589713
30. Matsuo K, Yasutomi Y. Mycobacterium bovis Bacille Calmette-Guerin as a Vaccine Vector for Global Infectious Disease Control. Tuberc Res Treat 2011; 2011:574591. doi: 10.1155/2011/574591 PMID: 22567267
31. Zheng YQ, Naguib YW, Dong Y, Shi YC, Bou S, Cui Z. Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Expert Rev Vaccines 2015; 14(9):1255–1275. PMID: 26268434
32. Chege GK, Burgers WA, Stutz H, Meyers AE, Chapman R, Kiravu A, et al. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol 2013 May; 87(9):5151–5160. doi: 10.1128/JVI.03178-12 PMID: 23449790
33. Sampson SL, Dascher CC, Sambandamurthy VK, Russell RG, Jacobs WR Jr, Bloom BR, et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 2004 May; 72(5):3031–3037. PMID: 15102816
34. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, Gatell JM, et al. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 2007 Sep; 81(17):9408–9418. PMID: 17596303
35. McAdam RA, Weisbrod TR, Martin J, Scuderi JD, Brown AM, Cirillo JD, et al. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect Immun 1995 Mar; 63(3):1004–1012. PMID: 7868221
36. Borsuk S, Mendum TA, Fagundes MQ, Michelon M, Cunha CW, McFadden J, et al. Auxotrophic complementation as a selectable marker for stable expression of foreign antigens in Mycobacterium bovis BCG. Tuberculosis (Edinb) 2007 Nov; 87(6):474–480.
37. Chapman R, Shephard E, Stutz H, Douglass N, Sambandamurthy V, Garcia I, et al. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells. PLoS One 2012; 7(3):e32769. doi: 10.1371/journal.pone.0032769 PMID: 22479338
38. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 2002 Oct; 8(10):1171–1174. PMID: 12219086
39. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998 May 10; 244(2):365–396. PMID: 9601507
40. Price PJ, Torres-Dominguez LE, Brandmuller C, Sutter G, Lehmann MH. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine 2013 Sep 6; 31 (39):4231–4234. doi: 10.1016/j.vaccine.2013.03.017 PMID: 23523404
41. Mercer AA, Schmidt A, Weber O editors. Poxviruses.; 2007.
42. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997 Nov 24; 238(2):198–211. PMID: 9400593
43. Gheorghiu M, Lagrange PH, Fillastre C. The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J Biol Stand 1988 Jan; 16(1):15–26. PMID: 3350821
44. Parish T, Stolker NG editors. Mycobacteria protocols.: Springer protocols; 2001.
45. Burgers WA, Shephard E, Monroe JE, Greenhalgh T, Binder A, Hurter E, et al. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 2008 Feb; 24(2):195–206. doi: 10.1089/aid.2007.0205 PMID: 18240957
46. Y. J. Shen. An investigation into the use of lumpy skin disease virus as a vaccine vector for a potential HIV-1 vaccineUniversity of Cape Town; 2010.
47. Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, Bourn W, et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. Journal of General Virology 2006; 87(2):399–410.
48. Columb MO, Sgadai S. Multiple comparisons. Current Anaesthesia & Critical Care 2006; 17:233–236.
49. Chapman R, Chege G, Shephard E, Stutz H, Williamson AL. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res 2010 Jun; 8(4):282–298. PMID: 20353397
50. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010 Mar; 16(3):324–328. doi: 10.1038/nm.2108 PMID: 20173754
51. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010 Mar; 16 (3):319–323. doi: 10.1038/nm.2089 PMID: 20173752
52. Kong WP, Wu L, Wallstrom TC, Fischer W, Yang ZY, Ko SY, et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009 Mar; 83(5):2201–2215. doi: 10.1128/JVI.02256-08 PMID: 19109395
53. Murphy K, P. editor. Janeway's Immunobiology.; 2011.
54. Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, Vogt J, et al. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 2009 Jul; 83(14):7176–7184. doi: 10.1128/JVI.00687-09 PMID: 19420086
55. Wong YC, Lin LC, Melo-Silva CR, Smith SA, Tscharke DC. Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection. J Virol Methods 2011 Jan; 171(1):295–298. doi: 10.1016/j.jviromet.2010.11.003 PMID: 21073901
56. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009 Mar; 15(3):293–299. doi: 10.1038/nm.1935 PMID: 19219024
57. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011 May 26; 473 (7348):523–527. doi: 10.1038/nature10003 PMID: 21562493
58. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013 Oct 3; 502(7469):100–104. doi: 10.1038/nature12519 PMID: 24025770
59. Saubi N, Mbewe-Mvula A, Gea-Mallorqui E, Rosario M, Gatell JM, Hanke T, et al. Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. PLoS One 2012; 7(8):e42559. doi: 10.1371/journal.pone.0042559 PMID: 22927933
60. Chapman R, Stutz H, Jacobs W Jr, Shephard E, Williamson AL. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice. PLoS One 2013 Aug 20; 8(8):e71601. doi: 10.1371/journal.pone.0071601 PMID: 23977084
61. Chapman R, Bourn WR, Shephard E, Stutz H, Douglass N, Mgwebi T, et al. The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen. PLoS One 2014 Jul 25; 9(7):e103314. doi: 10.1371/journal.pone.0103314 PMID: 25061753
62. van Faassen H, Dudani R, Krishnan L, Sad S. Prolonged antigen presentation, APC-, and CD8+ T cell turnover during mycobacterial infection: comparison with Listeria monocytogenes. J Immunol 2004 Mar 15; 172(6):3491–3500. PMID: 15004149
63. van Faassen H, Saldanha M, Gilbertson D, Dudani R, Krishnan L, Sad S. Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset. J Immunol 2005 May 1; 174(9):5341–5350. PMID: 15843531
64. Hess J, Schaible U, Raupach B, Kaufmann SH. Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv Immunol 2000; 75:1–88. PMID: 10879281
65. Al-Zarouni M, Dale JW. Expression of foreign genes in Mycobacterium bovis BCG strains using different promoters reveals instability of the hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strains. Tuberculosis (Edinb) 2002; 82(6):283–291.
66. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol 2011 Jan; 85(2):733–741. doi: 10.1128/JVI.02030-10 PMID: 21047960
67. Johansen P, Stamou P, Tascon RE, Lowrie DB, Stockinger B. CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells. Eur J Immunol 2004 Jan; 34(1):91–97. PMID: 14971034
68. Kemball CC, Pack CD, Guay HM, Li ZN, Steinhauer DA, Szomolanyi-Tsuda E, et al. The antiviral CD8+ T cell response is differentially dependent on CD4+ T cell help over the course of persistent infection. J Immunol 2007 Jul 15; 179(2):1113–1121. PMID: 17617604
69. Ramsburg EA, Publicover JM, Coppock D, Rose JK. Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent. J Immunol 2007 May 15; 178(10):6350–6358. PMID: 17475864
70. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006 Mar; 12(3):289–295. PMID: 16520776
71. Someya K, Xin KQ, Matsuo K, Okuda K, Yamamoto N, Honda M. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 2004 Sep; 78(18):9842–9853. PMID: 15331719
72. Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A 2005 Mar 22; 102(12):4512–4517. PMID: 15753288
73. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006 Jun 15; 107(12):4781–4789. PMID: 16467198
74. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. HIV-1-specific IFN-gamma/IL-2secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 2005 May 17; 102(20):7239–7244. PMID: 15872023
75. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010 May 27; 6(5): e1000917. doi: 10.1371/journal.ppat.1000917 PMID: 20523897